CN106916205B - Antibacterial hexapeptide and derivatives and application thereof - Google Patents
Antibacterial hexapeptide and derivatives and application thereof Download PDFInfo
- Publication number
- CN106916205B CN106916205B CN201710211273.4A CN201710211273A CN106916205B CN 106916205 B CN106916205 B CN 106916205B CN 201710211273 A CN201710211273 A CN 201710211273A CN 106916205 B CN106916205 B CN 106916205B
- Authority
- CN
- China
- Prior art keywords
- antibacterial
- trp
- arg
- drug
- acinetobacter baumannii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 claims abstract description 41
- 241000588626 Acinetobacter baumannii Species 0.000 claims abstract description 37
- 229940079593 drug Drugs 0.000 claims abstract description 37
- OVBRGKZTKQSNRM-JTRKXDDTSA-N 2-[[(9s,12s,15s,21s,30s,33s)-9-[(3-amino-4-hydroxyphenyl)methyl]-33-(2-amino-2-oxoethyl)-21-carbamoyl-12-(2-methylpropyl)-8,11,14,17,19,23,29,32,35-nonaoxo-30-propan-2-yl-19$l^{4}-thia-7,10,13,16,22,28,31,34-octazaspiro[5.29]pentatriacontan-15-yl]methyl]p Chemical compound N([C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCCCCC(=O)N[C@H](C[S+]([O-])CC(=O)N[C@@H](CC(C(O)=O)C(O)=O)C(=O)N[C@H](C(N[C@@H](CC=1C=C(N)C(O)=CC=1)C(=O)N1)=O)CC(C)C)C(N)=O)C(C)C)C(=O)C21CCCCC2 OVBRGKZTKQSNRM-JTRKXDDTSA-N 0.000 claims abstract description 13
- 208000032536 Pseudomonas Infections Diseases 0.000 claims 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 abstract description 60
- 241000894006 Bacteria Species 0.000 abstract description 15
- 230000002949 hemolytic effect Effects 0.000 abstract description 12
- 231100000419 toxicity Toxicity 0.000 abstract description 12
- 230000001988 toxicity Effects 0.000 abstract description 12
- 238000000034 method Methods 0.000 abstract description 9
- 208000035143 Bacterial infection Diseases 0.000 abstract description 6
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 abstract description 6
- 208000022362 bacterial infectious disease Diseases 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 239000003607 modifier Substances 0.000 abstract description 4
- 201000010099 disease Diseases 0.000 abstract description 3
- 238000010532 solid phase synthesis reaction Methods 0.000 abstract description 3
- 241000192125 Firmicutes Species 0.000 abstract description 2
- 230000002147 killing effect Effects 0.000 abstract description 2
- 229940117803 phenethylamine Drugs 0.000 abstract description 2
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 24
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 24
- 239000000243 solution Substances 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 208000015181 infectious disease Diseases 0.000 description 12
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 229920001184 polypeptide Polymers 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101800004361 Lactoferricin-B Proteins 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229960000484 ceftazidime Drugs 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 206010041925 Staphylococcal infections Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000035473 Communicable disease Diseases 0.000 description 4
- 241000194032 Enterococcus faecalis Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101800005149 Peptide B Proteins 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940032049 enterococcus faecalis Drugs 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000014912 Central Nervous System Infections Diseases 0.000 description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
- 229930182566 Gentamicin Natural products 0.000 description 3
- 206010062255 Soft tissue infection Diseases 0.000 description 3
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229960002518 gentamicin Drugs 0.000 description 3
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 3
- CFFMZOZGXDAXHP-HOKBLYKWSA-N lactoferricin Chemical compound C([C@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@H](C(=O)N1)[C@@H](C)O)=O)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CFFMZOZGXDAXHP-HOKBLYKWSA-N 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 206010033078 Otitis media Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010043958 Peptoids Proteins 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 208000013223 septicemia Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- LITBAYYWXZOHAW-XDZRHBBOSA-N (2s,5r,6r)-6-[[(2r)-2-[(4-ethyl-2,3-dioxopiperazine-1-carbonyl)amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2s,3s,5r)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4$l^{6}-thia-1-azabicyclo[3.2.0]hept Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 LITBAYYWXZOHAW-XDZRHBBOSA-N 0.000 description 1
- XXMFJKNOJSDQBM-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydrate Chemical compound [OH3+].[O-]C(=O)C(F)(F)F XXMFJKNOJSDQBM-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZUVPWWASXUUVFX-UHFFFAOYSA-M 4-hydroxybutyl(trimethyl)azanium;iodide Chemical compound [I-].C[N+](C)(C)CCCCO ZUVPWWASXUUVFX-UHFFFAOYSA-M 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000012984 antibiotic solution Substances 0.000 description 1
- 238000002802 antimicrobial activity assay Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 238000002898 library design Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960002260 meropenem Drugs 0.000 description 1
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108010005636 polypeptide C Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an antibacterial hexapeptide, which has a sequence as follows: Arg-Arg-Trp-Trp-Arg-Trp. Is applied to the preparation of the medicine for treating or preventing bacterial infection. The invention also provides an antibacterial hexapeptide derivative, which has the sequence as follows: Arg-Arg-Trp-Trp-Arg-Trp-beta-phenylethylamine. Is applied to the preparation of the medicine for treating or preventing bacterial infection. The bacteria are drug-resistant acinetobacter baumannii. The artificially designed and synthesized antibacterial hexapeptide and phenethylamine modifier thereof can be conveniently obtained by a solid-phase synthesis method. The synthetic antibacterial peptide and the derivatives thereof have broad-spectrum killing activity on gram-positive bacteria and gram-negative bacteria, particularly the derivatives thereof have stronger antibacterial activity on drug-resistant acinetobacter baumannii, have extremely low hemolytic toxicity, and can be applied to medicines for treating or preventing diseases caused by the drug-resistant acinetobacter baumannii.
Description
Technical Field
The invention relates to an antibacterial hexapeptide, derivatives thereof and application thereof, belonging to the technical field of biology.
Background
Worldwide, the number of bacteria infected patients reaches 15 hundred million, the number of dead people is 460 million, and the high death rate caused by the infection of multidrug resistant bacteria (MDRB) seriously threatens public health. The annual costs of prevention and treatment of bacterial infections in europe and the united states are as high as 70 billion euros and 65 billion dollars, and developing countries are burdened with this cost. The rapid spread of MDRB infection worldwide is closely related to antibiotic abuse and its development and development break, i.e., no new structural class of antibiotics was developed between 1962 and 2000; only 3 new structural types of antibacterial agents have entered the market since 2000. The American society for Infectious Diseases (IDSA) called for the encouragement of antibiotic development and funding since 2004, and 10 antibacterial drugs with completely new structures were developed before 2020. It is predicted that the development of anti-MDRB infection drugs will progress rapidly.
Acinetobacter Baumannii (AB) is a serious nosocomial pathogen that causes respiratory, blood, urinary, soft tissue and central nervous system infections that are transmitted between patients by direct or indirect contact. According to infection monitoring data in 2006-2007 foreign hospitals, the detection rate of acinetobacter baumannii in hospital infection is four times higher, and serious and even fatal infection can be caused in patients with low immunity. It can cause severe infectious diseases such as ventilator-associated pneumonia, septicemia, meningitis, otitis media, skin soft tissue infection, urinary system infection and central nervous system infection. Increased morbidity and mortality due to acinetobacter baumannii infection is referred to as "gram-negative MRSA". In conventional AB infections, the incidence of multi-drug resistant acinetobacter baumannii (MRAB) increased from 23% in 2004 to 63% in 2014, with an average incidence also significantly higher than other gram-negative bacteria (44% vs 13%). At present, 95% of MRAB has resistance to ceftriaxone, and 90% of MRAB has drug resistance to ceftazidime, levofloxacin, meropenem, piperacillin-tazobactam and other drugs, and is a great problem in treatment of clinical drug-resistant bacteria infection diseases. Therefore, screening of antibacterial agents with novel structures to cope with MRAB infection will become a hot spot for new drug development.
The antibacterial peptide (AMP) is a short peptide existing in all organisms, has the characteristics of cationic property and amphipathy, has various structures, is an important component of a natural immune system of the organisms to resist the invasion of pathogenic bacteria, and keeps stable and efficient in the biological evolution process. To date, about 5000 AMP sequences have been reported in the literature, of which 74 have entered the drug development stage. As AMP mainly takes bacterial cell membranes as action targets, the AMP is obviously different from the action mechanism of the traditional antibiotics, has obvious antibacterial effect on MDRB and is the candidate structure type with the most development potential for resisting MDRB. However, natural AMP still has problems of long amino acid sequence, high production cost, poor enzyme stability, easy degradation in vivo, and cytolytic toxicity, which are seriously problematic in clinical applications. The sequence of the non-natural small molecule antibacterial peptide (sAMP) obtained by a chemical synthesis method only consists of 3-9 amino acid residues, and due to the existence of non-natural amino acids (such as D-type amino acids or amino acid residue modifiers), the peptide has the advantages of remarkable activity, simple structure, easiness in synthesis, good stability, high safety and the like, and is widely concerned by researchers. Therefore, the discovery of sAMP and the analogues thereof with strong antibacterial activity, good enzyme resistance stability and high in vivo safety by a chemical synthesis method is an effective way for solving the MRAB infection problem.
Disclosure of Invention
In view of the existing problems, the first object of the present invention is to provide an antibacterial hexapeptide. The second purpose of the invention is to provide the application of the antibacterial hexapeptide, the third purpose of the invention is to provide an antibacterial hexapeptide derivative, and the fourth purpose is to provide the application of the antibacterial hexapeptide derivative. The antibacterial hexapeptide and the antibacterial hexapeptide derivative have broad-spectrum antibacterial activity on gram bacteria, wherein the antibacterial hexapeptide derivative has efficient inhibition effect on the growth of drug-resistant acinetobacter baumannii, and the antibacterial hexapeptide and the derivative thereof have low toxicity.
In order to achieve the first object, the technical scheme of the invention is as follows: an antibacterial hexapeptide characterized by: the sequence of the antibacterial hexapeptide is as follows: Arg-Arg-Trp-Trp-Arg-Trp.
In order to achieve the second object, the invention has the technical scheme that: the antibacterial hexapeptide is applied to preparing medicines for treating or preventing bacterial infection.
In order to achieve the third object, the technical solution of the present invention is: an antibacterial hexapeptide derivative characterized by: the sequence of the antibacterial hexapeptide derivative is as follows: Arg-Arg-Trp-Trp-Arg-Trp-beta-phenylethylamine (antimicrobial peptide b).
In order to achieve the fourth object, the technical solution of the present invention is: the antibacterial hexapeptide derivative is applied to preparing medicines for treating or preventing bacterial infection.
Further: the bacteria are drug-resistant acinetobacter baumannii. Herein, the drug-resistant acinetobacter baumannii is a drug-resistant acinetobacter baumannii in a broad sense, and includes single drug-resistant acinetobacter baumannii and multi-drug-resistant acinetobacter baumannii.
The idea of the invention is as follows: in the natural antibacterial peptide Lactoferricin B4-9On the basis of RRWQWR, a virtual combined library design technology, analysis software and websites such as DNAstar, Bioedit, sequence logo and the like are combined, and after a plurality of tests, a brand new polypeptide sequence RRWWRW (Arg-Arg-Trp-Trp-Arg-Trp) with antibacterial activity is found, and the polypeptide sequence still has remarkable antibacterial activity after the C-terminal phenethyl amination. Novel antibacterial hexapeptide and its derivative as compared with LfcinB4-9The antibacterial agent has better bactericidal effect and no hemolytic toxicity, particularly, the derivative of the antibacterial agent has stronger bactericidal activity to the drug-resistant acinetobacter baumannii, has small hemolytic toxicity, and is expected to be used for research and development of new drugs for treating bacterial infection, particularly drug-resistant acinetobacter baumannii.
The invention discloses an antibacterial hexapeptide phenylethylamine modifier (antibacterial peptide B), an antibacterial hexapeptide (antibacterial peptide a) and a natural antibacterial peptide Lactoferricin B, which are prepared by a Pioneer polypeptide synthesizer produced by American application systems biology company based on a solid-phase method4-9RRWQWR。
The antibacterial hexapeptide and the derivative thereof are detected by an agar hole diffusion method and a 96-well plate method, and the natural antibacterial peptide Lactoferricin B synthesized in advance is used4-9RRWQWR is used as a contrast for bactericidal activity detection, and the result shows that the bactericidal activity of the antibacterial hexapeptide and the derivative thereof is obviously stronger than that of the contrast natural antibacterial peptide Lactoferricin B4-9Bactericidal activity of RRWQWR. Compared with the antibacterial peptide a, the antibacterial peptide b disclosed by the invention can effectively inhibit the growth of drug-resistant acinetobacter baumannii under the condition of low concentration. Can be applied to medicines for treating or preventing diseases caused by drug-resistant acinetobacter baumannii, such as severe infectious diseases caused by drug-resistant acinetobacter baumannii, such as ventilator-associated pneumonia, septicemia, meningitis, otitis media, skin soft tissue infection, urinary system infection, central nervous system infection and the like.
The antibacterial peptide has the possibility of acting on higher organisms including human cells while being sterilized efficiently, because the antibacterial peptide acts in a mode of perforating cell membranes so that the cells are subjected to leakage death. Thus, whether the antibacterial peptide can make red blood cells or notLeakage is a criterion for toxicity, and if the antimicrobial peptide is capable of leaking hemoglobin from red blood cells, its OD can be detected490Values determine the magnitude of toxicity. Experiments show that the hemolysis rate of the antibacterial hexapeptide derivative is still very low under high concentration, and the hemolysis toxicity of the antibacterial hexapeptide derivative is very low.
The invention has the beneficial effects that: the artificially designed and synthesized antibacterial hexapeptide and phenethylamine modifier thereof can be conveniently obtained by a solid-phase synthesis method. The synthetic antibacterial peptide and the derivatives thereof have broad-spectrum killing activity on gram-positive bacteria and gram-negative bacteria, particularly the derivatives thereof have stronger antibacterial activity on drug-resistant acinetobacter baumannii, have extremely low hemolytic toxicity, and can be applied to medicines for treating or preventing diseases caused by the drug-resistant acinetobacter baumannii.
Drawings
FIG. 1 is a mass spectrum of the antibacterial hexapeptide derivative of the present invention.
FIG. 2 is a mass spectrum of antibacterial hexapeptide.
Detailed Description
The invention is further described below with reference to specific examples:
example 1:
chemically synthesizing antibacterial peptide a and antibacterial peptide B and a control antibacterial peptide Lactoferricin B4-9.
Antibacterial peptide a RRWWRW (Arg-Arg-Trp-Trp-Arg-Trp)
Antibacterial peptide b RRWWRW-PEA (Arg-Arg-Trp-Trp-Arg-Trp-beta-phenylethylamine)
1. Preparation of antibacterial peptide b (Arg-Arg-Trp-Trp-Arg-Trp-beta-phenylethylamine):
a. after the resin was washed with 4 times of DMF and completely dried, 10mL of a mixed solution of 20% (piperidine: DMF by mass) piperidine and DMF was added, followed by shaking for 1min and drying, and then 10mL of a mixed solution of 20% (piperidine: DMF by mass) piperidine and DMF was added, followed by shaking for 30 min; the reaction vessel was dried and the resin was washed with 4 times the amount of DMF to ensure no piperidine residue and the resin particles were checked for blue color with ninhydrin.
b. Add Fmoc protected amino acid (1mmol), 2.1mL of 0.45M HBTM/HOBT (1mmol), 248uL DIEA (2mmol) solution to the resin and shake for 30 min; drying the reaction container, washing the resin with 4 times of DMF, checking with ninhydrin, if the resin is colorless, preparing the resin again, and if the resin is blue, adding amino acid to react; repeating the amino acid ligation reaction until the synthesis of the polypeptide is finished; after the coupling is finished, using low-concentration trifluoroacetic acid to perform cracking, using ether to perform precipitation, adding the precipitate into a solvent (tetrahydrofuran or a mixed solvent thereof), then adding phenylethylamine to perform reaction, using high-concentration trifluoroacetic acid to remove a protecting group after the reaction is finished, and using ether to perform precipitation.
c. The polypeptide-resin was added to a mixed solution of 1mL acetic acid (AcOH), 2mL Trifluoroethanol (TFE), and 7mL Dichloromethane (DCM) and stirred at room temperature for 1 h; the resin was filtered and washed with 2 times the amount of a mixed solution of TFE/DCM (volume ratio 2:8) to ensure recovery of all the product; distilling and concentrating the product solution to less than 5 mL; adding ether to a test tube containing 100mL of the above concentrated solution to see if the fully protected polypeptide is dissolved in ether; if the insoluble, adding the glacial ethyl ether into the test tube again to promote the product to be separated out, and performing suction filtration to obtain a crude product; if the product is dissolved, adding water into the ether to precipitate the product, and then carrying out suction filtration to obtain a crude product.
d. Weighing 100mg of the dried crude solid polypeptide, dissolving in 10mL of 0.1% trifluoroacetic acid (TFA), filtering the sample with 0.22 μm filter membrane, and separating and purifying by reversed phase high performance liquid chromatography (RP-HPLC); eluting with 0.1% TFA water solution (A) and 0.1% Acetonitrile (ACN) solution (B) under gradient elution condition of 0-60% B for 30min, collecting eluate, and freeze drying in freeze dryer (-50 deg.C); the purified dried antimicrobial peptide was purity measured by HPLC and the molecular mass was determined by Mass Spectrometry (MS) to be consistent with the theoretically calculated molecular weight. The antibacterial peptide synthesis, purification and identification experiments are completed by Shanghai Ziye Biotech limited.
2. Antibacterial peptide a and antibacterial peptide Lfcin B4-9Preparation of RRWQWR
Synthesis of antimicrobial peptide a and antimicrobial peptide Lactoferricin B according to the standard Fmoc solid phase procedure4-9The synthetic peptide was purified by reverse phase HPLC (Vydac 218TP1022 column 2.2 × 25cm) using ethyl acetateElution with nitrile/water/trifluoroacetic acid system, MALDI-TOF and EPI mass spectrometry. Antibacterial peptide synthesis was performed by Shanghai purple zone Biotech, Inc.
Example 2
Antimicrobial peptide antimicrobial activity assay
Various standard strains used below were purchased from the Guangdong province culture Collection of microorganisms, and drug-resistant bacteria were provided by the third military medical science.
Detecting antibacterial activity of synthetic antibacterial peptide B and antibacterial peptide a by agar plate diffusion method, and using natural antibacterial peptide Lfcin B4-9As a control, the bactericidal activity of antibacterial peptide b and antibacterial peptide a of the present invention was evaluated.
The antibacterial activity of the antibacterial peptide is determined according to the following steps:
a. recovering strains: respectively picking a proper amount of escherichia coli, staphylococcus aureus, acinetobacter baumannii, pseudomonas aeruginosa, enterococcus faecalis, MRSA, single drug resistant acinetobacter baumannii (resistant to ceftazidime, the same below) and multiple drug resistant acinetobacter baumannii (resistant to both gentamicin and ceftazidime, the same below) by using an inoculating loop, streaking and marking in respective culture media. The culture was carried out in an inverted incubator at 37 deg.C (12-16 h).
b. And (3) strain culture: selecting single colony to 100ml liquid MHB culture solution, placing at 37 deg.C, rotating at 160, and shake culturing (12-16 h).
c. Preparation of bacterial suspension the turbidity of the prepared bacterial suspension was about 0.5 McLeod, at which time the bacterial colony count was about 1.5 × 108cfu/ml, then diluted to 10 at a ratio of 1:10005-106cfu/ml bacterial suspension.
d. Bacteriostatic experiments: respectively and uniformly coating diluted escherichia coli, staphylococcus aureus, acinetobacter baumannii, pseudomonas aeruginosa, enterococcus faecalis, MRSA, single drug-resistant acinetobacter baumannii and multi-drug-resistant acinetobacter baumannii suspension on 40mL of solid LB culture medium according to the amount of 0.2mL per plate (the diameter of the plate is 150 mm); after the culture medium is completely solidified, 6/plate holes with the diameter of 8mm are punched, and the plate holes are marked as +/-/CAZ/A/B/C, and respectively represent a positive control (gentamicin), a negative control (deionized water), ceftazidime and three polypeptides (A is antibacterial peptide a, B is antibacterial peptide B, and C is LfcinB 64-9). Adding 50ul of 1mg/ml gentamicin solution into the "+" hole; "-" well 50. mu.l deionized water; 50ul of 1mg/ml ceftazidime solution is added into the CAZ hole; 50ul of 1mg/ml antimicrobial peptide solution was added to each A/B/C well. Standing at 4 ℃ for 3h, culturing in a constant-temperature incubator at 37 ℃, observing the size of a macroscopic inhibition zone after 12h, and measuring the diameter of the inhibition zone. Each peptide was independently performed 3 times under each strain.
TABLE 11 antimicrobial Activity of the antimicrobial peptides at mg/ml against various bacteria
Note: CAZ-ceftazidime; "-" indicates no significant zone of inhibition
It is seen from table 1 above that the bactericidal activity of the antimicrobial peptide b and the antimicrobial peptide a of the present invention is significantly and better than that of the natural antimicrobial peptide.
Example 3 detection of bacteriostatic Activity of synthetic antimicrobial peptides
Various standard strains used below were purchased from the Guangdong province culture Collection of microorganisms, and drug-resistant bacteria were provided by the third military medical science.
The bactericidal activity of the synthetic antibacterial peptide is detected by adopting a 96-well plate method, and the natural antibacterial peptide Lfcin B is used4-9As a control, the bacteriostatic activity of the antimicrobial peptides a, b was evaluated.
The antibacterial activity of the antibacterial peptide is determined according to the following steps:
a. escherichia coli, staphylococcus aureus, acinetobacter baumannii, pseudomonas aeruginosa, enterococcus faecalis, MRSA, single drug-resistant acinetobacter baumannii and multi-drug-resistant acinetobacter baumannii are cultured on a sterilization NA culture medium plate overnight, a single colony is selected and inoculated in a sterilization MHB culture solution, and the culture is carried out for 18-24 h at 37 ℃ and 170 r/min.
b. Diluting the cultured bacterial liquid to 105-106cfu/ml bacterial suspension. After 2 times of the peptoid solution to be detected with the bacteriostatic activity is continuously diluted, the peptoid solution to be detected is added into a 96-hole micro-culture plate, and the holes 1 and 12 are left unused (so that the marginal effect is avoided to cause inaccurate data). Adding 160 mul of diluted bacteria liquid into the 2 nd hole, and adding the diluted bacteria liquid into the 3-9 th holesAdding 40 μ l of antibacterial peptide stock solution (with a concentration of 1280 μ g/ml) into the 2 nd well, mixing, sucking 100 μ l, adding into the 3 rd well, sequentially diluting to the 9 th well, and discarding 100 μ l. The final concentrations of the antimicrobial peptidomimetics thus determined were:
the peptide mimetics to be tested were diluted to the following concentrations (μ g/ml) at a concentration of 1280 μ g/ml:
| numbering | A2 | A3 | A4 | A5 | A6 | A7 | A8 | A9 |
| Concentration of | 256 | 128 | 64 | 32 | 16 | 8 | 4 | 2 |
The control was grown in well 10 and positive control (Imipenem) in well 11, and 160. mu.l of the inoculum and 40. mu.l of the antibiotic solution of the same concentration were added and 100. mu.l was discarded. Each antimicrobial peptide was done 3 times in parallel. After incubation at 37 ℃ for 16h, OD was measured with ELISA reader600Value, minimum OD600The minimum concentration corresponding to the value is the MIC value of the antimicrobial peptide. According to the result, MICs of the antibacterial peptides a and b on escherichia coli, staphylococcus aureus, acinetobacter baumannii, pseudomonas aeruginosa, enterococcus faecalis, MRSA, single drug resistant acinetobacter baumannii and multiple drug resistant acinetobacter baumannii are calculated respectively.
TABLE 2 Minimum Inhibitory Concentration (MIC) of antimicrobial peptides against different bacteria
The smaller the minimum inhibitory concentration value in the table above, the stronger the antibacterial ability. MIC ratio of synthetic antimicrobial peptides a and B of the invention Lfcin B4-9Both are small, and the antibacterial ability of the synthetic antibacterial peptides a and B is greatly stronger than that of the antibacterial peptide Lfcin B4-9However, the antibacterial peptide b has better bactericidal effect particularly on drug-resistant bacteria acinetobacter baumannii.
Example 4 in vitro hemolytic Activity assay
This example is used to determine whether the synthetic antibacterial peptide has hemolytic activity to human erythrocytes, and the antibacterial peptide a and the antibacterial peptide Lfcin B synthesized by solid phase chemistry4-9As a control. Blood samples used were taken from sterile sheep blood.
The hemolytic activity was determined by the following steps:
a. the sterilized sheep blood was centrifuged at 3000rpm/min for 5min and washed 3 times with PBS buffer, the centrifugation was repeated, the supernatant was discarded, and the erythrocytes were retained.
b.0.1ml of erythrocyte solution was diluted with 9.9ml of PBS (final concentration of erythrocytes is 1%), 200. mu.l of antimicrobial peptide at concentrations of 512, 256, 128, 64, 32, 16, 8. mu.g/ml, respectively, was mixed with 200. mu.l of the diluted erythrocyte solution, incubated at 37 ℃ for 1 hour, centrifuged at 4000rpm/min for 5 minutes, the suspension was transferred to a 96-well ELISA plate and absorbance of the suspension was measured at 414nm, respectively, and the hemolysis rate per well was calculated. 0.01mol/L PBS was used as a negative control, and 0.1% Triton-X100 (polyethylene glycol octyl phenyl ether) was used as a positive control. The hemolysis rate (%) × (test tube absorbance-negative control tube absorbance)/(positive control tube absorbance-negative control tube absorbance) × 100%.
c. Hemolytic rate experiments with antimicrobial peptides a and Lfcin B4-9As a control, the experiment was repeated three times independently.
TABLE 4 results of hemolysis and blood circulation promotion test of three antibacterial peptides
The smaller the value of hemolysis of the antimicrobial peptide, the less hemolytic toxicity of the antimicrobial peptide. From the results in the table, it can be seen that the hemolytic toxicity of the antimicrobial peptides a and b is below 5%, and the increase in hemolytic toxicity is not significant even at elevated concentrations. Compared with the control natural antibacterial peptide, the hemolytic toxicity is very low, and particularly, the hemolysis phenomenon is not greatly generated at high concentration, so that the method is an important basis for the next step of medicament preparation.
<210>1
<211>6
<212>PRT
<213> Artificial Synthesis
<220>
<223> antimicrobial peptide a
<400>1
Arg-Arg-Trp-Trp-Arg-Trp
1 5 6
<210>1
<211>6
<212>PRT
<213> Artificial Synthesis
<220>
<223> antimicrobial peptide b
<400>2
Arg-Arg-Trp-Trp-Arg-Trp-beta-phenylethylamine
1 56
Claims (1)
1. An application of an antibacterial hexapeptide derivative in preparing a medicament for treating or preventing multiple drug-resistant acinetobacter baumannii, single drug-resistant acinetobacter baumannii and pseudomonas aeruginosa infection, wherein the sequence of the antibacterial hexapeptide derivative is as follows: Arg-Arg-Trp-Trp-Arg-Trp-beta-phenylethylamine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710211273.4A CN106916205B (en) | 2017-03-31 | 2017-03-31 | Antibacterial hexapeptide and derivatives and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710211273.4A CN106916205B (en) | 2017-03-31 | 2017-03-31 | Antibacterial hexapeptide and derivatives and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106916205A CN106916205A (en) | 2017-07-04 |
| CN106916205B true CN106916205B (en) | 2020-10-13 |
Family
ID=59567158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710211273.4A Active CN106916205B (en) | 2017-03-31 | 2017-03-31 | Antibacterial hexapeptide and derivatives and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106916205B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102368983B1 (en) * | 2019-02-28 | 2022-03-03 | 단디바이오사이언스 주식회사 | Polypeptide having antibacterial activity, composition for preventing or treating sepsis comprising the same, and antibacterial composition |
| CN113248572B (en) * | 2021-04-30 | 2023-04-11 | 重庆理工大学 | Anti-multidrug-resistant bacteria cyclopeptide and application thereof |
| CN113999285B (en) * | 2021-12-02 | 2023-02-14 | 浙江大学 | Antibacterial heptapeptide and application thereof |
| CN115746094B (en) * | 2022-10-25 | 2024-04-05 | 重庆理工大学 | Antibacterial peptide and preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992009300A1 (en) * | 1990-11-21 | 1992-06-11 | Iterex Pharmaceuticals Ltd. Partnership | Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures |
| CN102432672A (en) * | 2011-12-13 | 2012-05-02 | 重庆理工大学 | Novel synthesis antibacterial peptides and application thereof |
| CN104292301A (en) * | 2014-11-06 | 2015-01-21 | 西南大学 | Micromolecule synthesized anti-microbial peptide, as well as preparation method and application thereof |
-
2017
- 2017-03-31 CN CN201710211273.4A patent/CN106916205B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN106916205A (en) | 2017-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106916205B (en) | Antibacterial hexapeptide and derivatives and application thereof | |
| CN107344958B (en) | Antibacterial pentapeptide derivative and application thereof | |
| CN117586352B (en) | Antibacterial polypeptide APH220 based on salivary glands of Hirudinaria manillensis and application thereof | |
| CN113999285B (en) | Antibacterial heptapeptide and application thereof | |
| Park et al. | Bactericidal activities and action mechanism of the novel antimicrobial peptide Hylin a1 and its analog peptides against Acinetobacter baumannii infection | |
| Bhat et al. | Antibacterial and antioomycete activities of a novel designed RY12WY peptide against fish pathogens | |
| Choi et al. | Antifungal effect of CopA3 monomer peptide via membrane-active mechanism and stability to proteolysis of enantiomeric D-CopA3 | |
| CN113292636A (en) | Antibacterial hexapeptide and application thereof | |
| CN110156875B (en) | Antibacterial peptide H5-p5, and preparation method and application thereof | |
| CN110054664B (en) | Side chain fatty acid modified antibacterial peptide analogue containing D-type amino acid and synthesis and application thereof | |
| CN110066320B (en) | Cyclic peptide resisting multiple drug-resistant bacteria and preparation method and application thereof | |
| CN116874614A (en) | Antibacterial polypeptide APH171 with high activity and low cracking effect, and preparation method and application thereof | |
| CN114805495B (en) | Enzymolysis-resistant branched antibacterial peptide Pal-CRKP, and preparation method and application thereof | |
| CN115785220B (en) | Tryptophan-enriched antibacterial peptide with high protease stability and preparation method and application thereof | |
| CN106518974A (en) | Antimicrobial peptide | |
| CN113185598B (en) | Antibacterial peptide targeting gram-negative bacteria and preparation method and application thereof | |
| CN112409457B (en) | Antibacterial polypeptide and application thereof | |
| CN113185577B (en) | Low-toxicity broad-spectrum antibacterial peptide with different charge arrangement modes and different charge types and application thereof | |
| CN108610428B (en) | Antibacterial fusion peptide and preparation method and application thereof | |
| CN112724202A (en) | Antibacterial peptide and application thereof | |
| CN114989246B (en) | FK3 polypeptide analogue and application thereof | |
| JP5196407B2 (en) | Peptide compound having biological activity, its preparation and its application | |
| CN113583090B (en) | Arnopyrin modified peptide with antibacterial activity and synthesis method and application thereof | |
| JP2005247721A (en) | Antimicrobial peptide having reduced hemolysis, and method for using the same | |
| TWI522110B (en) | Novel securities peptides and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221114 Address after: 411201 No. 15, Ya'ai Road, Jiuhua Economic Development Zone, Xiangtan City, Hunan Province Patentee after: Hunan Paixun Biotechnology Co.,Ltd. Address before: No.69 Hongguang Avenue, Banan District, Chongqing Patentee before: Chongqing University of Technology |
|
| TR01 | Transfer of patent right |